GLOBAL ANTICOAGULANTS MARKET FORECAST 2021-2028

The global anticoagulants market is projected to register a CAGR of 8.42%, generating revenue of $66236.0 million by 2028. The base year considered for the market study is 2020, and the forecast years are from 2021 to 2028.

Anticoagulants are drugs that help prevent blood clots. These drugs are prescribed to individuals with a higher risk of developing clots, while reducing the likelihood of suffering from severe conditions, such as heart attacks and strokes.
global-anticoagulants-market

To learn more about this report, request a free sample copy

Key factors propelling the global anticoagulants market growth:

  • Surging prevalence of chronic diseases
    • The most common chronic diseases, including inherited deficiencies, lead to clinical blood clotting.
    • Heparins are used to address a condition’s underlying fault, and are presently gaining immense traction. As a result, this factor is anticipated to increase the demand for anticoagulant drugs.
  • Advancements in technology
  • Rising approval of novel oral anticoagulants (NOACs)

Major restraining factors limiting the global anticoagulants market growth:

  • Side effects associated with anticoagulants treatment
  • High price of NOACs
  • Stringent government regulations
    • Strict regulations serve the public with an enhanced assurance of therapeutic safety.
    • However, progressive concerns regarding the increasingly complex regulatory scenarios lead to higher expenses linked with drug development and its administration.
    • In some cases, the stringent guidelines for drug development processes often take ten years, therefore delaying the entire treatment process.

The report scope of the global anticoagulants market assessment includes the segmentation analysis of application, route of administration, and drug class. One of these segments is further classified to provide a detailed analysis of the studied market.

Market by Application:

  • Atrial Fibrillation & Heart Attack
    • The atrial fibrillation & heart attack segment, in terms of the application category, is expected to harbor the highest market share.
    • Atrial fibrillation, also known as AFib or AF, is an irregular heartbeat that can lead to various heart-related complications.
    • Thus, anticoagulant medications are used to prevent the growth of blood clots in the arteries.
    • Moreover, heparin’s anticoagulant effect is fast-acting as well as dose-related.
  • Deep Vein Thrombosis (DVT)
    • The deep vein thrombosis (DVT) segment is anticipated to lead the application category.
    • Deep vein thrombosis (DVT) refers to the clotting of blood that usually occurs in leg veins. However, they can also develop in arm veins, as well as the cerebral and the mesenteric veins.
    • DVT is often associated with impaired quality of life, mainly when post-thrombotic syndrome develops.
    • Therefore, the treatment of such diseases is of utmost importance, and is anticipated to bolster the demand for anticoagulants.
  • Pulmonary Embolism (PE)
  • Stroke
  • Other Applications

Geographically, the global anticoagulants market has been segmented based on four major regions, which includes:

  • North America: The United States and Canada
    • North America is set to dominate the global market during the forecast period.
    • The easy availability of novel therapeutics, an increase in the obese and geriatric population, and high healthcare awareness, are among the primary factors driving the market growth.
    • The region’s market progresses at a significant pace, owing to the introduction of NOACs.
    • Warfarin remains the drug of choice, with the number of prescriptions of this class of drugs being high, when compared to other oral anticoagulants.
  • Europe: The United Kingdom, Germany, Italy, France, Belgium, Russia, Poland, and Rest of Europe
  • Asia Pacific: India, Australia & New Zealand, China, South Korea, Japan, Thailand, Indonesia, Vietnam, and Rest of Asia Pacific
    • The Asia Pacific is projected to be the fastest-growing region for the anticoagulants market, over the forecast years.
    • The Asia Pacific presents lucrative opportunities for the players operating in the region’s anticoagulant drugs market, attributed to the rapid rise in the prevalence of cardiovascular disease and VTE, the high population base, and economic developments.
    • The increasing number of research and development activities to develop newer therapeutics across emerging economies, such as India and China, is expected to further reinforce the market growth in the Asia Pacific.
  • Rest of World: Latin America, the Middle East & Africa

Major market players in the global anticoagulants market are: 

  • Abbott laboratories
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Daiichi Sankyo
  • Pfizer Inc
  • Others

Key strategies adopted by some of these companies:

In October 2020, Johnson & Johnson announced the acquisition completion of Momenta Pharmaceuticals, Inc, an enterprise that develops and discovers novel therapies for immune-mediated ailments, in an all-cash deal for approximately $6.5 billion. Also, in October 2020, the Parkinson’s Foundation and Sanofi collaborated to advance the accessibility of free genetic counseling and testing, particularly for people with Parkinson’s disease.

Key findings of the global anticoagulants market:

  • Emerging markets observe numerous lucrative opportunities.
  • The growing aging population plays an essential role in accelerating market demand.
  • The global anticoagulants market growth is associated with an increase in hip and knee replacement surgeries.
  • NOACs is the fastest-growing drug class.

 

Frequently Asked Questions and Answers (FAQs):

  • How has the COVID-19 pandemic augmented the growth of the global anticoagulants market?

   A: The pharmaceutical industry is continually advancing at an increased rate, primarily due to the increasing number of COVID-19 infections. This factor is majorly attributed to the global anticoagulants market growth, as it comprises a significant part of the industry.

  • What is the impact of direct oral anticoagulants (DOACs) on the global anticoagulants market?

   A: The development of direct oral anticoagulants (DOACs) signified a remarkable advancement in the field of anticoagulation. Besides, DOACs have proven efficacy across various indications, with increased accessibility in terms of anticoagulation. As a result, this factor widely contributes to the global anticoagulants market growth.

  • What is a significant challenge likely to hinder the use of anticoagulant drugs?

   A: The possibility of drug interaction with other medications increases the chances of allergy and excessive bleeding. Hence, this is a major challenge, likely to hinder the use of anticoagulants.

 

TABLE OF CONTENTS
  1. RESEARCH SCOPE & METHODOLOGY
    1. STUDY OBJECTIVES
    2. SCOPE OF STUDY
    3. METHODOLOGY
    4. ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    1. MARKET SIZE & ESTIMATES
    2. MARKET OVERVIEW
  3. MARKET DYNAMICS
    1.    KEY DRIVERS
      1. SURGING PREVALENCE OF CHRONIC DISEASE
      2. ADVANCEMENTS IN TECHNOLOGY
      3. RISING APPROVAL OF NOVEL ORAL ANTICOAGULANTS (NOACS)
    2.    KEY RESTRAINTS
      1. SIDE EFFECTS ASSOCIATED WITH ANTICOAGULANTS TREATMENT
      2. HIGH PRICE OF NOACS
      3. STRINGENT GOVERNMENT REGULATIONS
  4. KEY ANALYTICS
    1.    PORTER'S FIVE FORCES ANALYSIS
      1. THREAT OF NEW ENTRY
      2. THREAT OF SUBSTITUTION
      3. BUYER'S POWER
      4. SUPPLIER'S POWER
      5. COMPETITIVE RIVALRY
    2. IMPACT OF COVID-19 ON ANTICOAGULANTS MARKET
    3. OPPORTUNITY MATRIX
    4. VENDOR LANDSCAPE
    5. KEY INVESTMENT INSIGHTS
  5. MARKET BY APPLICATION
    1. ATRIAL FIBRILLATION & HEART ATTACK
    2. PULMONARY EMBOLISM (PE)
    3. DEEP VEIN THROMBOSIS (DVT)
    4. STROKE
    5. OTHER APPLICATIONS
  6. MARKET BY ROUTE OF ADMINISTRATION
    1. ORAL ANTICOAGULANTS
    2. INJECTABLE ANTICOAGULANTS
  7. MARKET BY DRUG CLASS
    1.    NOACS
      1. XARELTO
      2. ELIQUIS
      3. PRADAXA
      4. SAVAYSA & LIXIANA
      5. BEVYXXA
    2. HEPARINS & LOW-MOLECULAR-WEIGHT HEPARINS (LMWHS)
    3. VITAMIN K ANTAGONISTS
    4. OTHER DRUG CLASS
  8. GEOGRAPHICAL ANALYSIS
    1.    NORTH AMERICA
      1. MARKET SIZE & ESTIMATES
      2. KEY GROWTH ENABLERS
      3. KEY CHALLENGES
      4. KEY PLAYERS
      5.    COUNTRY ANALYSIS
        1. UNITED STATES
        2. CANADA
    2.     EUROPE
      1. MARKET SIZE & ESTIMATES
      2. KEY GROWTH ENABLERS
      3. KEY CHALLENGES
      4. KEY PLAYERS
      5.    COUNTRY ANALYSIS
        1. GERMANY
        2. FRANCE
        3. UNITED KINGDOM
        4. ITALY
        5. RUSSIA
        6. BELGIUM
        7. POLAND
        8. REST OF EUROPE
    3.     ASIA PACIFIC
      1. MARKET SIZE & ESTIMATES
      2. KEY GROWTH ENABLERS
      3. KEY CHALLENGES
      4. KEY PLAYERS
      5.    COUNTRY ANALYSIS
        1. CHINA
        2. JAPAN
        3. AUSTRALIA & NEW ZEALAND
        4. INDIA
        5. SOUTH KOREA
        6. THAILAND
        7. INDONESIA
        8. VIETNAM
        9. REST OF ASIA PACIFIC
    4.     REST OF WORLD
      1. MARKET SIZE & ESTIMATES
      2. KEY GROWTH ENABLERS
      3. KEY CHALLENGE
      4. KEY PLAYERS
      5.    REGIONAL ANALYSIS
        1. LATIN AMERICA
        2. MIDDLE EAST & AFRICA
  9. COMPETITIVE LANDSCAPE
    1.    KEY STRATEGIC DEVELOPMENTS
      1. MERGER & ACQUISITIONS
      2. PRODUCT LAUNCH & DEVELOPMENTS
      3. PARTNERSHIP, CONTRACT/ AGREEMENT & COLLABORATION
      4. BUSINESS EXPANSION/ APPROVAL/ ANNOUNCEMENT
    2.    COMPANY PROFILE
      1. ABBOTT LABORATORIES
      2. ALEXION PHARMACEUTICAL INC
      3. ASPEN PHARMACARE HOLDINGS LIMITED
      4. BAYER AG
      5. BOEHRINGER INGELHEIM GMBH
      6. BRISTOL-MYERS SQUIBB COMPANY
      7. DAIICHI SANKYO
      8. REDDY'S LABORATORIES
      9. GLAXOSMITHKLINE PLC
      10. JOHNSON & JOHNSON
      11. LEO PHARMA AS
      12. MERCK & CO
      13. NOVARTIS AG
      14. PFIZER INC
      15. SANOFI
LIST OF TABLES

TABLE 1: MARKET SNAPSHOT – ANTICOAGULANTS

TABLE 2: GLOBAL ANTICOAGULANTS MARKET, BY APPLICATION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 3: GLOBAL ANTICOAGULANTS MARKET, BY APPLICATION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 4: GLOBAL ATRIAL FIBRILLATION & HEART ATTACK MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 5: GLOBAL ATRIAL FIBRILLATION & HEART ATTACK MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 6: GLOBAL PULMONARY EMBOLISM (PE) MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 7: GLOBAL PULMONARY EMBOLISM (PE) MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 8: GLOBAL DEEP VEIN THROMBOSIS (DVT) MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 9: GLOBAL DEEP VEIN THROMBOSIS (DVT) MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 10: GLOBAL STROKE MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 11: GLOBAL STROKE MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 12: GLOBAL OTHER APPLICATIONS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 13: GLOBAL OTHER APPLICATIONS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 14: GLOBAL ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 15: GLOBAL ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 16: GLOBAL ORAL ANTICOAGULANTS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 17: GLOBAL ORAL ANTICOAGULANTS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 18: GLOBAL INJECTABLE ANTICOAGULANTS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 19: GLOBAL INJECTABLE ANTICOAGULANTS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 20: GLOBAL ANTICOAGULANTS MARKET, BY DRUG CLASS, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 21: GLOBAL ANTICOAGULANTS MARKET, BY DRUG CLASS, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 22: GLOBAL NOACS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 23: GLOBAL NOACS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 24: GLOBAL NOACS MARKET, BY TYPE, FORECAST YEARS, 2018-2021 (IN $ MILLION)

TABLE 25: GLOBAL HEPARINS & LMWH MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 26: GLOBAL HEPARINS & LMWH MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 27: GLOBAL VITAMIN K ANTAGONISTS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 28: GLOBAL VITAMIN K ANTAGONISTS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 29: GLOBAL OTHER DRUG CLASS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 30: GLOBAL OTHER DRUG CLASS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 31: GLOBAL ANTICOAGULANTS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 32: GLOBAL ANTICOAGULANTS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 33: NORTH AMERICA ANTICOAGULANTS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 34: NORTH AMERICA ANTICOAGULANTS MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 35: LEADING PLAYERS OPERATING IN NORTH AMERICA ANTICOAGULANTS MARKET

TABLE 36: EUROPE ANTICOAGULANTS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 37: EUROPE ANTICOAGULANTS MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 38: LEADING PLAYERS OPERATING IN EUROPE ANTICOAGULANTS MARKET

TABLE 39: ASIA PACIFIC ANTICOAGULANTS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 40: ASIA PACIFIC ANTICOAGULANTS MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 41: LEADING PLAYERS OPERATING IN ASIA PACIFIC ANTICOAGULANTS MARKET

TABLE 42: REST OF WORLD ANTICOAGULANTS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 43: REST OF WORLD ANTICOAGULANTS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 44: LEADING PLAYERS OPERATING IN REST OF WORLD ANTICOAGULANTS MARKET

LIST OF FIGURES

FIGURE 1: CHRONIC CONDITIONS IN PATIENTS HOSPITALIZED WITH COVID-19 IN THE UNITED STATES

FIGURE 2: PORTER’S FIVE FORCE ANALYSIS

FIGURE 3: OPPORTUNITY MATRIX

FIGURE 4: VENDOR LANDSCAPE

FIGURE 5: KEY INVESTMENT INSIGHTS

FIGURE 6: GLOBAL ANTICOAGULANTS MARKET, BY APPLICATION, IN 2020

FIGURE 7: GLOBAL ANTICOAGULANTS MARKET, BY ATRIAL FIBRILLATION & HEART ATTACK, 2021-2028 (IN $ MILLION)

FIGURE 8: GLOBAL ANTICOAGULANTS MARKET, BY PULMONARY EMBOLISM (PE), 2021-2028 (IN $ MILLION)

FIGURE 9: GLOBAL ANTICOAGULANTS MARKET, BY DEEP VEIN THROMBOSIS (DVT), 2021-2028 (IN $ MILLION)

FIGURE 10: GLOBAL ANTICOAGULANTS MARKET, BY STROKE, 2021-2028 (IN $ MILLION)

FIGURE 11: GLOBAL ANTICOAGULANTS MARKET, BY OTHER APPLICATIONS, 2021-2028 (IN $ MILLION)

FIGURE 12: GLOBAL ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, IN 2020

FIGURE 13: GLOBAL ANTICOAGULANTS MARKET, BY ORAL ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)

FIGURE 14: GLOBAL ANTICOAGULANTS MARKET, BY INJECTABLE ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)

FIGURE 15: GLOBAL ANTICOAGULANTS MARKET, BY DRUG CLASS, IN 2020

FIGURE 16: GLOBAL ANTICOAGULANTS MARKET, BY NOACS, 2021-2028 (IN $ MILLION)

FIGURE 17: GLOBAL NOACS MARKET, BY XARELTO, 2018-2021 (IN $ MILLION)

FIGURE 18: GLOBAL NOACS MARKET, BY ELIQUIS, 2018-2021 (IN $ MILLION)

FIGURE 19: GLOBAL NOACS MARKET, BY PRADAXA, 2018-2021 (IN $ MILLION)

FIGURE 20: GLOBAL NOACS MARKET, BY SAVAYSA & LIXIANA, 2018-2021 (IN $ MILLION)

FIGURE 21: GLOBAL NOACS MARKET, BY BEVYXXA, 2018-2021 (IN $ MILLION)

FIGURE 22: GLOBAL ANTICOAGULANTS MARKET, BY HEPARINS & LOW-MOLECULAR-WEIGHT HEPARINS (LMWHS), 2021-2028 (IN $ MILLION)

FIGURE 23: GLOBAL ANTICOAGULANTS MARKET, BY VITAMIN K ANTAGONISTS, 2021-2028 (IN $ MILLION)

FIGURE 24: GLOBAL ANTICOAGULANTS MARKET, BY OTHER DRUG CLASS, 2021-2028 (IN $ MILLION)

FIGURE 25: NORTH AMERICA ANTICOAGULANTS MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)

FIGURE 26: UNITED STATES ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)

FIGURE 27: CANADA ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)

FIGURE 28: EUROPE ANTICOAGULANTS MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)

FIGURE 29: GERMANY ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)

FIGURE 30: FRANCE ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)

FIGURE 31: UNITED KINGDOM ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)

FIGURE 32: ITALY ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)

FIGURE 33: RUSSIA ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)

FIGURE 34: BELGIUM ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)

FIGURE 35: POLAND ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)

FIGURE 36: REST OF EUROPE ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)

FIGURE 37: ASIA PACIFIC ANTICOAGULANTS MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)

FIGURE 38: CHINA ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)

FIGURE 39: JAPAN ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)

FIGURE 40: AUSTRALIA & NEW ZEALAND ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)

FIGURE 41: INDIA ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)

FIGURE 42: SOUTH KOREA ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)

FIGURE 43: THAILAND ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)

FIGURE 44: INDONESIA ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)

FIGURE 45: VIETNAM ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)

FIGURE 46: REST OF ASIA PACIFIC ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)

FIGURE 47: REST OF WORLD ANTICOAGULANTS MARKET, REGIONAL OUTLOOK, 2020 & 2028 (IN %)

FIGURE 48: LATIN AMERICA ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)

FIGURE 49: MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)

Request For A Free Sample